<DOC>
	<DOCNO>NCT00516841</DOCNO>
	<brief_summary>To evaluate efficacy voloxicimab administer 15 mg/kg qwk subject platinum-resistant , advanced epithelial ovarian cancer primary peritoneal cancer .</brief_summary>
	<brief_title>A Phase 2 , Single-Arm Study Volociximab Monotherapy Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer Primary Peritoneal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Must give write informed consent authorization require local law ( e.g. , Protected Health Information [ PHI ] ) . Females age ≥18 year old time inform consent . Advanced ( Stage III IV ) , histologicallydocumented epithelial ovarian cancer primary peritoneal cancer ( exclude small , roundcell histology ) . Radiologicallydocumented evidence progressive disease . Platinumresistant disease define best response SD disease progression within 6 month discontinue platinumbased chemotherapy ( carboplatinum , cisplatinum , another organoplatinum compound ) . Progression follow treatment topotecan liposomal doxorubicin . Three few prior chemotherapy regimen ( include platinumbased therapy ) . At least 1 measurable target lesion accordance RECIST criterion assess clinical response ( tumor within previously irradiate field designate nontarget ) . ECOG Performance Status ≤1 . Life expectancy &gt; 12 week . Available paraffin block unstained paraffin section glass slide contain representative tumor tissue recent tumor biopsy/resection . Subjects childbearing potential must willing practice effective contraception study willing able continue contraception least 6 month last dose study treatment ( 5 half life ) . Screening clinical laboratory value : Absolute neutrophil count &lt; 1500/µL Platelet count &lt; 75,000/µL Hemoglobin &lt; 8.5 g/dL ( hemoglobin may support transfusion , erythropoietin , approve hematopoietic growth factor ; darbopoeitin [ Aranesp® ] permit ) Serum bilirubin &gt; 2.0 x upper limit normal ( ULN ) AST ALT &gt; 2.5 x ULN ( AST ALT &gt; 5 × ULN subject liver metastasis ) Serum creatinine &gt; 2.0 mg/dL International normalized ratio ( INR ) &gt; 1.5 Activated partial thromboplastin time ( aPTT ) &gt; 1.5 × ULN Clinically significant peripheral vascular disease . Nonepithelial ovarian tumor . Active infection require systemic antibiotic , antiviral , antifungal include HIV/AIDS , hepatitis B , hepatitis C infection . History abdominal fistula , gastrointestinal ( GI ) perforation , intraabdominal abscess within 6 month prior Day 1 . Serious , nonhealing wound , bone fracture . Known central nervous system brain metastasis . History uncontrolled psychiatric condition within 6 month prior Day 1 . History malignancy within 3 year Day 1 , except adequately treat carcinoma situ cervix , ductal carcinoma situ ( DCIS ) breast , basal squamous cell skin cancer . Evidence autoimmune disease include , limited , ulcerative colitis , Crohn 's disease , rheumatoid arthritis ( RA ) , systemic lupus erythematosus ( SLE ) sceloderma , another disease immune function immune competence know impaired . Any history lymphoproliferative disorder . Known human antimurine antibody ( HAMA ) and/or human antichimeric antibody ( HACA ) . Any medical condition may exacerbate bleeding , include know bleed disorder coagulation defect , thrombocytopenia , active gastric duodenal ulcer , history GI bleeding . Significant hemoptysis within one year prior Study Day 1 . Any investigational , anticancer therapy within 6 week prior Day 1 . Any noninvestigational , anticancer therapy within 4 week prior Day 1 . Prior treatment antiangiogenic agent . Subjects require treatment anticoagulant exception lowdose Aspirin® ( ≤81 mg/day ) , warfarin ( ≤1 mg/day ) , heparin IV catheter patency . Subjects take concomitant immunomodulatory agent include , limited , interferon , interleukin , systemic steroid , cyclosporine , tacrolimus , calcineurin inhibitor , chronic lowdose methotrexate , azathioprine . ( The use inhale intranasal steroid oral steroid dose ≤10 mg/day prednisone equivalent permit . ) Active , unstable severe cardiovascular disease , include poorly control angina , congestive heart failure ( CHF ) , arrhythmias , myocardial infarction ( MI ) , cardiomyopathy , atrioventricular ( AV ) block , electrocardiogram ( ECG ) evidence acute ischemia , significant conduction abnormality . History thromboembolic cerebrovascular event , stroke , transient ischemic attack ( TIA ) . ( Note : Prior history deep vein thrombosis exclude subject participate study . ) Pregnant ( positive pregnancy test ) lactating . Inability comply study followup procedure . Any condition , opinion Investigator , make subject unsuitable study participation . Known hypersensitivity murine chimeric antibody . Major surgery within 4 week prior Day 1 .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>epithelial ovarian cancer</keyword>
	<keyword>peritoneal cancer</keyword>
	<keyword>platinum-resistant ovarian cancer</keyword>
	<keyword>Platinum-Resistant Advanced Epithelial Ovarian Cancer Primary Peritoneal Cancer</keyword>
</DOC>